A CD4+ T CELL CLONE SELECTED FROM A CML PATIENT AFTER DONOR LYMPHOCYTE INFUSION RECOGNIZES BCR-ABL BREAKPOINT PEPTIDES BUT NOT TUMOR CELLS1

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

1994 • 5,204 citations

Graft-versus-leukemia reactions after bone marrow transplantation

1990 • 2,781 citations

Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]

1995 • 2,026 citations

Chronic Myeloid Leukemia

1999 • 1,639 citations

The Biology of Chronic Myeloid Leukemia

1999 • 1,308 citations

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

1997 • 1,290 citations

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology

1999 • 389 citations

Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse

1994 • 358 citations

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation

1995 • 341 citations

Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant

1998 • 328 citations

Use of Leukemic Dendritic Cells for the Generation of Antileukemic Cellular Cytotoxicity Against Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

1997 • 309 citations

Specific human cellular immunity to bcr-abl oncogene-derived peptides

1996 • 300 citations

Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses

2000 • 250 citations

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.

1998 • 244 citations

Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11

1999 • 231 citations

Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide

1996 • 200 citations

Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules

1995 • 193 citations

Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]

1993 • 162 citations

Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism

2000 • 154 citations

Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.

1992 • 146 citations

BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors

1996 • 115 citations

Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells.

1995 • 106 citations

HLA-DR1–Restricted bcr-abl (b3a2)-Specific CD4+ T Lymphocytes Respond to Dendritic Cells Pulsed With b3a2 Peptide and Antigen-Presenting Cells Exposed to b3a2 Containing Cell Lysates

1997 • 105 citations

Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response

1997 • 104 citations

Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.

1997 • 95 citations

CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner

1998 • 72 citations

Peptides derived from the whole sequence of BCR‐ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes

1997 • 64 citations

A BCR-ABL Oncoprotein p210b2a2 Fusion Region Sequence Is Recognized by HLA-DR2a Restricted Cytotoxic T Lymphocytes and Presented by HLA-DR Matched Cells Transfected With an Iib2a2 Construct

1999 • 62 citations

HLA Class II Restricted T-Cell Reactivity to a Developmentally Regulated Antigen Shared by Leukemic Cells and CD34+ Early Progenitor Cells

1997 • 49 citations

Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.

2000 • 23 citations

CTLs Specific for bcr-abl Joining Region Segment Peptides Fail to Lyse Leukemia Cells Expressing p210 bcr-abl Protein

1998 • 23 citations

Hairy Cell Leukemia-Specific Recognition by Multiple Autologous HLA-DQ or DP-Restricted T-Cell Clones

1999 • 17 citations